CN114796260B - Oral care composition and preparation method thereof - Google Patents
Oral care composition and preparation method thereof Download PDFInfo
- Publication number
- CN114796260B CN114796260B CN202210737850.4A CN202210737850A CN114796260B CN 114796260 B CN114796260 B CN 114796260B CN 202210737850 A CN202210737850 A CN 202210737850A CN 114796260 B CN114796260 B CN 114796260B
- Authority
- CN
- China
- Prior art keywords
- parts
- oral care
- care composition
- hydroxypropyl
- sodium alginate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
An oral care composition and a preparation method thereof belong to the field of oral care, and the oral care composition consists of hydroxypropyl guar gum, hydroxypropyl trimethyl ammonium chloride chitosan, sodium alginate aqueous solution, hydroxypropyl-beta-cyclodextrin, steviosin, mentha carboxamide ethanol solution, gallic acid, glycyrrhizic acid, paeonol, tea polyphenol, carbamide peroxide, glutathione, epsilon-polylysine and deionized water; the preparation method comprises two steps of medicament thermal dissolution and gelling and thickening; the oral care composition prepared by the invention has good antibacterial and bacteriostatic effects, does not contain triclosan and fluoride, and can treat common oral diseases and whiten teeth.
Description
Technical Field
The invention relates to an oral care composition and a preparation method thereof, belonging to the field of oral care.
Background
The oral health is very important for the whole body health of people, so that the teeth of people are fresh and cool, delicious dishes are enjoyed, and the virus infection and diseases such as coronary heart disease, diabetes, stomach diseases, newborn low body weight and the like can be avoided and reduced. Oral diseases are of various types, mainly including symptoms such as decayed teeth, cementum loss, oral ulcer, gingivitis, gingival atrophy, gingival bleeding, periodontitis and the like, because various bacteria bred due to eating sweet food and excessive sour food and improper tooth brushing or food residues remained in slits between teeth have unknown causes so far, and many oral diseases cannot be completely cured. Therefore, as people pay attention to the oral health concept, it is crucial to develop oral care composition products.
Most of the oral care compositions reported at present are bacteriostatic by adding triclosan or fluoride,
The purpose of sterilization is to realize the long-acting bacteriostasis or the effect of preventing decayed teeth by compounding triclosan or fluoride with other auxiliary materials. Triclosan, as a spectroscopic antimicrobial agent, acts on both gram-positive and gram-negative bacteria. The primary site of action of triclosan against microorganisms is the cytoplasmic membrane of the bacteria. However, triclosan poses a certain threat to the human body, and as to the side effects of triclosan, the teaching of the university of Virginia has found through experiments that a product containing triclosan reacts with tap water containing chlorine to form a substance called "Colorfuran", i.e., chloroform. Chloroform was used as an anesthetic, and animal experiments show that the substance can cause damage to heart and liver, has mild teratogenicity, and can induce liver cancer and arrhythmia of mice. The harm of fluoride is also a public theory, too much fluorine is taken, which affects the development of teeth and bones slightly, fluorosis and dental fluorosis occur, and nausea, vomiting, arrhythmia and other acute fluorosis are caused seriously. Furthermore, the frequent use of fluorine-containing oral care products can produce fluorine-resistant strains, and the caries prevention effect can be greatly reduced. There is therefore an urgent need in the market for oral care composition products that are free of triclosan and fluoride.
Chinese patent CN106236597A discloses an oral care composition and its application, which comprises: perlite; polyphosphoric acid inositol compound selected from phytic acid, inositol pentaphosphate, inositol tetraphosphate, inositol triphosphate, and one or more of alkali metal salt, alkaline earth metal salt and ammonium salt thereof; an orally acceptable carrier. The oral care composition obtained in the patent has only the efficacy of whitening teeth, has no inhibition and killing effect on oral bacteria, and has no drug effect of treating oral diseases.
Chinese patent CN113995686A discloses an oral care composition with whitening function, which comprises the following raw materials in parts by weight: 10-36 parts of a composite friction agent, 0.1-5 parts of a bleaching agent and 1-10 parts of a covering agent; other oral care composition bases in parts; other oral care composition bases include: 10-25 parts of deionized water, 15-25 parts of a humectant, 1-5 parts of a tackifier, 1-3 parts of a surfactant, 0.1-0.5 part of a flavoring agent, 0.1-0.3 part of a sweetening agent, 0.3-0.5 part of a buffering agent and 0.1-0.3 part of a preservative. The oral care composition described in this patent still has only the function of whitening teeth and no other therapeutic effect for the combined treatment of oral diseases.
As can be seen from the above, the existing oral care composition has single curative effect, lacks of bacteriostatic and antibacterial functional products, and has few products for preventing and treating oral diseases, so that the development of the oral care composition with comprehensive functionality has great significance for oral health.
Disclosure of Invention
Aiming at the defects existing in the prior art, the invention provides an oral care composition and a preparation method thereof, and the following invention aims are realized: the prepared oral care composition has good antibacterial effect, does not contain triclosan and fluoride, can treat common oral diseases and has the function of whitening teeth.
In order to realize the purpose, the invention adopts the following technical scheme:
the oral care composition comprises the following raw materials in parts by mass:
1-3 parts of hydroxypropyl guar gum,
2-4 parts of hydroxypropyl trimethyl ammonium chloride chitosan,
2-5 parts of sodium alginate aqueous solution,
1.5-4.5 parts of hydroxypropyl-beta-cyclodextrin,
0.1 to 0.5 portion of steviosin,
1-2.5 parts of menthane carboxamide ethanol solution,
0.5-1 part of gallic acid,
0.4 to 1 part of glycyrrhizic acid,
0.2-1 part of paeonol,
0.5 to 1.2 parts of tea polyphenol,
6 to 11 parts of carbamide peroxide,
1-2.5 parts of glutathione,
0.5-2 parts of epsilon-polylysine,
75-100 parts of deionized water;
the molecular weight of the hydroxypropyl guar gum is 60000-85000 g/mol;
the molecular weight of the hydroxypropyl trimethyl ammonium chloride chitosan is 30000-60000 g/mol;
in the sodium alginate aqueous solution, the mass concentration of the sodium alginate is 0.99-1.96%;
in the menthane carboxamide ethanol solution, the mass ratio of menthane carboxamide to ethanol is 1-2: 18;
the preparation method of the oral care composition comprises two steps of medicament hot dissolving and gelling and thickening;
the following is a further improvement of the above technical solution:
step 1, hot dissolving medicament
Heating deionized water to 75-90 ℃, adding hydroxypropyl-beta-cyclodextrin at a stirring speed of 2000-3500 rpm, after completely dissolving, sequentially and slowly adding stevioside, gallic acid, glycyrrhizic acid, paeonol, tea polyphenol, glutathione and epsilon-polylysine, stirring for 0.5-1 hour at a stirring speed of 2000-3500 rpm, after completely dissolving, reducing the stirring speed to 500-1000 rpm, cooling to room temperature, then adding a menthane carboxamide ethanol solution and carbamide peroxide, and dissolving into a transparent solution to obtain a medicament solution.
Step 2, gelling and thickening
Adding hydroxypropyl trimethyl ammonium chloride chitosan into the medicament solution at the stirring speed of 3000-4500 rpm, adding a sodium alginate aqueous solution after the chitosan is completely dissolved, slowly adding hydroxypropyl guar gum, and continuously stirring for 0.5-1.5 hours after the addition is finished to obtain viscous colloidal liquid, namely the oral care composition.
Compared with the prior art, the invention has the following beneficial effects:
1. the oral care composition prepared by the invention has good antibacterial and bacteriostatic effects, does not contain triclosan and fluoride, and can treat common oral diseases and simultaneously has the function of whitening teeth;
2. the oral care composition prepared by the invention has a bacteriostasis rate of 94.4-96.2% on staphylococcus aureus, a bacteriostasis rate of 91.9-94.3% on escherichia coli and a bacteriostasis rate of 92.6-95.1% on candida albicans; can be used for treating halitosis, periodontitis, periodontal abscess, gingival hemorrhage and oral ulcer: after 7 days of use, the number of the effective persons is 30-36, the number of the effective persons is 16-22, the number of the ineffective persons is 8-10, after 15 days of use, the number of the effective persons is 39-43, the number of the effective persons is 11-17, and the number of the ineffective persons is 4-7; whitening effect on teeth: after 1 week of use, the tooth brightness is improved from 5 to 4, and after 1 month of use, the tooth brightness is improved to 3;
3. according to the invention, the gallic acid, glycyrrhizic acid, paeonol, tea polyphenol, hydroxypropyl trimethyl ammonium chloride chitosan and other antibacterial agents are compounded, and the hydroxypropyl-beta-cyclodextrin is added to perform a solubilizing effect on paeonol, gallic acid and other substances with poor water solubility, so that the obtained oral care composition has excellent broad-spectrum antibacterial performance;
4. according to the invention, by adding hydroxypropyl guar gum and combining the thickening and viscosity-increasing effects of two substances of hydroxypropyl trimethyl ammonium chloride chitosan and sodium alginate aqueous solution, a colloidal product which is good in viscosity and suitable for being smeared on the surface of teeth is obtained, the colloidal product can play a slow-release role in the added carbamide peroxide, and the problem of damage to tooth enamel caused by too fast release of carbamide peroxide is avoided while the tooth whitening effect is ensured to be remarkable.
Detailed Description
The following description of the preferred embodiments of the present invention is provided for the purpose of illustration and description, and is in no way intended to limit the invention.
Example 1: oral care composition and preparation method thereof
The oral care composition comprises the following raw materials in parts by mass:
2 parts of hydroxypropyl guar gum,
3 portions of hydroxypropyl trimethyl ammonium chloride chitosan,
3 parts of sodium alginate aqueous solution,
2.5 parts of hydroxypropyl-beta-cyclodextrin,
0.3 portion of steviosin,
2 parts of menthane carboxamide ethanol solution,
0.8 portion of gallic acid,
0.6 part of glycyrrhizic acid,
0.5 part of paeonol,
1 part of tea polyphenol,
9 parts of carbamide peroxide,
1.5 parts of glutathione,
1.3 parts of epsilon-polylysine,
90 parts of deionized water;
the molecular weight of the hydroxypropyl guar gum is 70000 g/mol;
the molecular weight of the hydroxypropyl trimethyl ammonium chloride chitosan is 50000 g/mol;
in the sodium alginate aqueous solution, the mass concentration of sodium alginate is 1.48%;
in the menthane carboxamide ethanol solution, the mass ratio of menthane carboxamide to ethanol is 1.5: 18;
the preparation method of the oral care composition comprises two steps of medicament hot dissolving and gelling and thickening;
1. medicament hot melting
Heating deionized water to 80 ℃, adding hydroxypropyl-beta-cyclodextrin at a stirring speed of 3000 r/min, after complete dissolution, sequentially and slowly adding stevioside, gallic acid, glycyrrhizic acid, paeonol, tea polyphenol, glutathione, epsilon-polylysine, stirring for 0.8 hour at a stirring speed of 3000 r/min, after complete dissolution, reducing the stirring speed to 700 r/min, cooling to room temperature, then adding a menthane carboxamide ethanol solution and carbamide peroxide, and dissolving into a transparent solution to obtain a medicament solution.
2. Gelling thickening
Adding hydroxypropyl trimethyl ammonium chloride chitosan into the medicament solution at the stirring speed of 3500 rpm, adding sodium alginate aqueous solution after completely dissolving, slowly adding hydroxypropyl guar gum, and continuously stirring for 1 hour after adding the materials to obtain viscous colloidal liquid, namely the oral care composition.
Example 2: oral care composition and preparation method thereof
The method comprises the following steps:
the oral care composition comprises the following raw materials in parts by mass:
1 part of hydroxypropyl guar gum,
2 parts of hydroxypropyl trimethyl ammonium chloride chitosan,
2 parts of sodium alginate aqueous solution,
1.5 parts of hydroxypropyl-beta-cyclodextrin,
0.1 part of steviosin,
1 part of menthol amide ethanol solution,
0.5 part of gallic acid,
0.4 part of glycyrrhizic acid,
0.2 part of paeonol,
0.5 part of tea polyphenol,
6 parts of carbamide peroxide,
1 part of glutathione,
0.5 part of epsilon-polylysine,
75 parts of deionized water;
the molecular weight of the hydroxypropyl guar gum is 60000 g/mol;
the molecular weight of the hydroxypropyl trimethyl ammonium chloride chitosan is 30000 g/mol;
in the sodium alginate aqueous solution, the mass concentration of the sodium alginate is 0.99 percent;
in the menthane carboxamide ethanol solution, the mass ratio of menthane carboxamide to ethanol is 1: 18;
the preparation method of the oral care composition comprises two steps of medicament hot dissolving and gelling and thickening;
1. medicine hot dissolving
Heating deionized water to 75 ℃, adding hydroxypropyl-beta-cyclodextrin at a stirring speed of 2000 rpm, after complete dissolution, sequentially and slowly adding stevioside, gallic acid, glycyrrhizic acid, paeonol, tea polyphenol, glutathione, epsilon-polylysine, stirring for 0.5 hour at a stirring speed of 2000 rpm, after complete dissolution, reducing the stirring speed to 500 rpm, cooling to room temperature, then adding a menthane carboxamide ethanol solution and carbamide peroxide, and dissolving into a transparent solution to obtain a medicament solution.
2. Gelling thickening
Adding hydroxypropyl trimethyl ammonium chloride chitosan into the medicament solution at the stirring speed of 3000 r/min, completely dissolving, then adding a sodium alginate aqueous solution, then slowly adding hydroxypropyl guar gum, and continuously stirring for 0.5 hour after the addition is finished to obtain viscous colloidal liquid, namely the oral care composition.
Example 3: oral care composition and preparation method thereof
The method comprises the following steps:
the oral care composition comprises the following raw materials in parts by mass:
3 portions of hydroxypropyl guar gum,
4 parts of hydroxypropyl trimethyl ammonium chloride chitosan,
5 parts of sodium alginate aqueous solution,
4.5 parts of hydroxypropyl-beta-cyclodextrin,
0.5 part of steviosin,
2.5 parts of menthane carboxamide ethanol solution,
1 part of gallic acid,
1 part of glycyrrhizic acid,
1 part of paeonol,
1.2 parts of tea polyphenol,
11 parts of carbamide peroxide,
2.5 parts of glutathione,
2 parts of epsilon-polylysine,
100 parts of deionized water;
the molecular weight of the hydroxypropyl guar gum is 85000 g/mol;
the molecular weight of the hydroxypropyl trimethyl ammonium chloride chitosan is 60000 g/mol;
in the sodium alginate aqueous solution, the mass concentration of sodium alginate is 1.96%;
in the menthane carboxamide ethanol solution, the mass ratio of menthane carboxamide to ethanol is 2: 18;
the preparation method of the oral care composition comprises two steps of medicament hot dissolving and gelling and thickening;
1. medicament hot melting
Heating deionized water to 90 ℃, adding hydroxypropyl-beta-cyclodextrin at a stirring speed of 3500 rpm, after complete dissolution, sequentially and slowly adding stevioside, gallic acid, glycyrrhizic acid, paeonol, tea polyphenol, glutathione, epsilon-polylysine, stirring for 1 hour at a stirring speed of 3500 rpm, after complete dissolution, reducing the stirring speed to 1000 rpm, cooling to room temperature, then adding a menthane carboxamide ethanol solution and carbamide peroxide, and dissolving into a transparent solution to obtain a medicament solution.
2. Gelling and thickening
Adding hydroxypropyl trimethyl ammonium chloride chitosan into the medicament solution at the stirring speed of 4500 rpm, adding sodium alginate aqueous solution after the chitosan is completely dissolved, slowly adding hydroxypropyl guar gum, and continuously stirring for 1.5 hours after the addition is finished to obtain viscous colloidal liquid, namely the oral care composition.
Comparative example 1: example 1 based on the absence of hydroxypropyl-. beta. -cyclodextrin
The oral care composition is prepared by replacing 2.5 parts of hydroxypropyl-beta-cyclodextrin in a specific formula with 2.5 parts of deionized water in an equivalent manner on the basis of example 1 according to the mass parts of the raw materials;
in the step 1, on the basis of the example 1, hydroxypropyl-beta-cyclodextrin is not added, and the other operations are the same as those in the example 1;
step 2 was performed as in example 1.
Comparative example 2: based on example 1, no hydroxypropyltrimethylammonium chloride chitosan and sodium alginate were added
The oral care composition is prepared by replacing 3 parts of hydroxypropyl trimethyl ammonium chloride chitosan and 3 parts of sodium alginate aqueous solution in a specific formula with 6 parts of hydroxypropyl guar gum on the basis of example 1 according to the mass parts of the raw materials;
step 1 was performed as in example 1;
in step 2, based on example 1, the operations were the same as in example 1 except that the hydroxypropyl trimethyl ammonium chloride chitosan and sodium alginate aqueous solution were not added.
Comparative example 3: based on the example 1, the hydroxypropyl guar gum, the hydroxypropyl trimethyl ammonium chloride chitosan and the sodium alginate aqueous solution are replaced by polyethylene glycol in equal amount
The oral care composition is prepared by replacing 2 parts of hydroxypropyl guar gum, 3 parts of hydroxypropyl trimethyl ammonium chloride chitosan and 3 parts of sodium alginate aqueous solution in a specific formula with 6 parts of hydroxypropyl guar gum in an equivalent manner on the basis of example 1 according to the mass parts of the raw materials;
step 1 was performed as in example 1;
in the step 2, on the basis of the example 1, the hydroxypropyl guar gum, the hydroxypropyl trimethyl ammonium chloride chitosan and the sodium alginate aqueous solution are not added, the polyethylene glycol is directly added into the medicament solution, and the other operations are the same as the example 1;
the molecular weight of the polyethylene glycol is 26000 g/mol.
Evaluation of pharmaceutical effect of oral care composition:
(1) evaluation of bacteriostatic Effect
After the oral care compositions obtained in examples 1, 2 and 3 were diluted to a mass concentration of 10wt% with deionized water, bacteriostatic experiments of three oral pathogenic bacteria, staphylococcus aureus, escherichia coli and candida albicans, were performed, and the results are shown in table 1 below:
TABLE 1
The data in table 1 show that, compared with examples 1, 2 and 3, comparative example 1 without hydroxypropyl- β -cyclodextrin is most effective in reducing the bacteriostatic effect, because the three antibacterial and bacteriostatic substances, i.e., gallic acid, glycyrrhizic acid and paeonol, have poor water solubility, and are difficult to exert the antibacterial and bacteriostatic effects without the solubilizing effect of hydroxypropyl- β -cyclodextrin, so that the bacteriostatic effect of comparative example 1 is greatly reduced; compared example 2 and comparative example 3 have not added hydroxypropyl trimethyl ammonium chloride chitosan and sodium alginate aqueous solution, the antibacterial effect has also obviously reduced, it can be seen that hydroxypropyl trimethyl ammonium chloride chitosan and sodium alginate also have positive antibacterial and bacteriostatic effects, and the broad-spectrum antibacterial performance of the oral care composition can be broadened.
(2) Evaluation of therapeutic Effect on oral diseases
240 volunteers diagnosed as halitosis, periodontitis, periodontal abscess, gingival bleeding and oral ulcer disease in outpatient service are selected for evaluating the treatment effect, the 240 volunteers are randomly divided into four groups of 1, 2, 3 and 4, 60 volunteers in each group, 1, 2 and 3 groups respectively use deionized water diluted solution with the mass concentration of 10wt% of the oral care composition prepared in the embodiments 1, 2 and 3, each volunteer gargles twice a day with 25 ml of the oral care composition diluted solution each time in the morning and evening, and the mouth of each time is gargled for about 5 minutes; 4 groups of compound chlorhexidine acetate gargle are given, and the conditions of using method, dosage and the like are consistent with those of 1 group, 2 groups and 3 groups; the evaluation standard is divided into three grades, and the effect is shown: the symptoms of halitosis, periodontitis, periodontal abscess, gingival hemorrhage and oral ulcer, etc. disappear completely or the main symptoms are relieved by more than half, the red swelling or abscess subsides, and the pain disappears or is greatly relieved. The method has the following advantages: the symptoms are improved, the pain of the volunteers is obviously reduced, and the volunteers definitely feel uncomfortable symptoms to a certain extent. And (4) invalidation: volunteers clearly showed no improvement in the condition. The results are shown in Table 2:
TABLE 2
The data in table 2 show that the oral care composition prepared by the invention has a significantly better treatment effect on oral diseases than the compound chlorhexidine acetate gargle.
(3) Evaluation of active oxygen sustained-release effect during use of oral care composition:
the rate of release of reactive oxygen species from carbamide peroxide in oral care compositions was determined by the potassium permanganate method using the following test principles:
5H 2 O 2 + 2MnO 4 - + 6H + =Mn 2 + + 5O 2 + 8H 2 O；
the calculation formula is w =4cV/m, wherein w is the active oxygen mass fraction,%, of the oral care composition at a certain time; v is the volume of potassium permanganate solution used for titration, mL; c is the concentration of the potassium permanganate standard solution, m is the mass of the oral care composition sample, g; in the specific test, the oral composition samples obtained in examples 1, 2 and 3 and comparative examples 1, 2 and 3 are respectively taken, deionized water with the mass of 50% of that of the sample is added to quickly dilute the sample uniformly and then stand, potassium permanganate standard solution is used for titration, and w values after standing for 3 minutes, 6 minutes and 9 minutes are tested, and the test data are shown in table 3:
TABLE 3
As can be seen from the data in Table 3, in comparison with examples 1, 2 and 3, in comparative example 1 without adding hydroxypropyl-beta-cyclodextrin, the speed of releasing active oxygen by carbamide peroxide is approximately equal to that of example 1, which shows that hydroxypropyl-beta-cyclodextrin has little influence on the process of releasing active oxygen by carbamide peroxide; in comparative example 2, the speed of releasing active oxygen by carbamide peroxide is obviously increased by a lot without adding hydroxypropyl trimethyl ammonium chloride chitosan and sodium alginate; in comparative example 3, the hydroxypropyl guar gum, the hydroxypropyl trimethyl ammonium chloride chitosan and the sodium alginate aqueous solution are replaced by polyethylene glycol in equal amount, the speed of releasing active oxygen by carbamide peroxide is fastest, the mass fraction of the active oxygen is already as low as 0.47 in 6 minutes, which indicates that carbamide peroxide is decomposed into hydrogen peroxide basically and completely in 6 minutes, and the instantaneous concentration of the hydrogen peroxide is too large, so that the damage risk to oral mucosa is increased.
(4) Evaluation experiment and results of tooth whitening effect:
examples 1, 2, and 3 above gave oral care compositions which were distributed to three groups of volunteers, 10 persons in each group having an average tooth brightness of 5 (the measuring tool was Vita 3D-MASTER color scale), and three groups of 30 persons underwent a use effect evaluation test for 1 month, using the method: once in the morning and at night, the oral care composition is applied to all teeth uniformly by using a toothbrush, the oral care composition is maintained for 10 minutes after the application is finished, and then the teeth are rinsed with clean water), and the experimental data is shown in table 4 (the data in the table is the most people brightness value, for example, 5 represents the most volunteers with the brightness value of 5):
TABLE 4
As can be seen from the data in Table 4, the whitening effect is significantly better in examples 1, 2 and 3 after 1 week from the start of the experiment, the tooth brightness of most volunteers is increased from 5 to 4, and the tooth brightness of most volunteers can reach 3 after 1 month from the start of the experiment.
Claims (1)
1. An oral care composition characterized by:
the oral care composition comprises the following raw materials in parts by mass: 2 parts of hydroxypropyl guar gum, 3 parts of hydroxypropyl trimethyl ammonium chloride chitosan, 3 parts of sodium alginate aqueous solution, 2.5 parts of hydroxypropyl-beta-cyclodextrin, 0.3 part of steviosin, 2 parts of menthyl amide ethanol solution, 0.8 part of gallic acid, 0.6 part of glycyrrhizic acid, 0.5 part of paeonol, 1 part of tea polyphenol, 9 parts of carbamide peroxide, 1.5 parts of glutathione, 1.3 parts of epsilon-polylysine and 90 parts of deionized water;
the molecular weight of the hydroxypropyl guar gum is 70000 g/mol; the molecular weight of the hydroxypropyl trimethyl ammonium chloride chitosan is 50000 g/mol; in the sodium alginate aqueous solution, the mass concentration of sodium alginate is 1.48%; in the menthane carboxamide ethanol solution, the mass ratio of menthane carboxamide to ethanol is 1.5: 18;
the preparation method of the oral care composition comprises two steps of medicament hot dissolving and gelling and thickening;
the medicament is hot-dissolved: heating deionized water to 80 ℃, adding hydroxypropyl-beta-cyclodextrin at a stirring speed of 3000 r/min, after complete dissolution, sequentially and slowly adding stevioside, gallic acid, glycyrrhizic acid, paeonol, tea polyphenol, glutathione, epsilon-polylysine, stirring for 0.8 hour at a stirring speed of 3000 r/min, after complete dissolution, reducing the stirring speed to 700 r/min, cooling to room temperature, then adding a menthane carboxamide ethanol solution and carbamide peroxide, and dissolving into a transparent solution to obtain a medicament solution;
the gelling and thickening: adding hydroxypropyl trimethyl ammonium chloride chitosan into the medicament solution at the stirring speed of 3500 rpm, adding sodium alginate aqueous solution after completely dissolving, slowly adding hydroxypropyl guar gum, and continuously stirring for 1 hour after adding the materials to obtain viscous colloidal liquid, namely the oral care composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210737850.4A CN114796260B (en) | 2022-06-28 | 2022-06-28 | Oral care composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210737850.4A CN114796260B (en) | 2022-06-28 | 2022-06-28 | Oral care composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114796260A CN114796260A (en) | 2022-07-29 |
| CN114796260B true CN114796260B (en) | 2022-09-27 |
Family
ID=82523265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210737850.4A Active CN114796260B (en) | 2022-06-28 | 2022-06-28 | Oral care composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114796260B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057306A (en) * | 1983-11-06 | 1991-10-15 | Hill Ira D | Method of manufacturing oral hygiene gels |
| CN101119739A (en) * | 2004-12-22 | 2008-02-06 | 高露洁-棕榄公司 | Methods for use of oral care compositions containing free-b-ring flavonoid anti-oxidants |
| CN101721336A (en) * | 2008-10-27 | 2010-06-09 | 上海利康消毒高科技有限公司 | Gargle with drinking safety and preparation method thereof |
| CN104163876A (en) * | 2014-08-25 | 2014-11-26 | 吉林君同行生物科技有限公司 | Chitosan quaternary ammonium salt product and preparation method thereof |
| CN105326901A (en) * | 2015-12-14 | 2016-02-17 | 北京同仁堂麦尔海生物技术有限公司 | Traditional Chinese medicine composition for treating and/or preventing oral diseases and preparing method thereof |
| US20180168981A1 (en) * | 2016-12-20 | 2018-06-21 | Colgate-Palmolive Company | Oral Care Compositions and Methods for Whitening Teeth |
| WO2022088724A1 (en) * | 2020-10-28 | 2022-05-05 | 南京中科游子生物技术研究院有限公司 | Green tea active substance mouthwash composition and preparation method therefor |
-
2022
- 2022-06-28 CN CN202210737850.4A patent/CN114796260B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057306A (en) * | 1983-11-06 | 1991-10-15 | Hill Ira D | Method of manufacturing oral hygiene gels |
| CN101119739A (en) * | 2004-12-22 | 2008-02-06 | 高露洁-棕榄公司 | Methods for use of oral care compositions containing free-b-ring flavonoid anti-oxidants |
| CN101721336A (en) * | 2008-10-27 | 2010-06-09 | 上海利康消毒高科技有限公司 | Gargle with drinking safety and preparation method thereof |
| CN104163876A (en) * | 2014-08-25 | 2014-11-26 | 吉林君同行生物科技有限公司 | Chitosan quaternary ammonium salt product and preparation method thereof |
| CN105326901A (en) * | 2015-12-14 | 2016-02-17 | 北京同仁堂麦尔海生物技术有限公司 | Traditional Chinese medicine composition for treating and/or preventing oral diseases and preparing method thereof |
| US20180168981A1 (en) * | 2016-12-20 | 2018-06-21 | Colgate-Palmolive Company | Oral Care Compositions and Methods for Whitening Teeth |
| WO2022088724A1 (en) * | 2020-10-28 | 2022-05-05 | 南京中科游子生物技术研究院有限公司 | Green tea active substance mouthwash composition and preparation method therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114796260A (en) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5560906A (en) | Non-alcoholic antimicrobial mouthwash for removal of dental plaque | |
| CN102639100A (en) | Antibacterial pharmaceutical composition for oral hygiene and treatment of oral diseases of microbial origin | |
| CN100502889C (en) | Oral and Dental Compositions | |
| US20100266990A1 (en) | Dental antimicrobial formulations and methods of using the same | |
| CN108743926A (en) | A kind of compositions of additives containing lysozyme | |
| US5167952A (en) | Therapeutic composition formulated as a dental rinse that stimulates Prostaglandin synthesis in the mouth to prevent plaque buildup on the teeth and Periodontal disease | |
| CN112545978A (en) | Oral care gel with effect of resisting helicobacter pylori in sustained manner and preparation method thereof | |
| CN112826751B (en) | Anti-allergy toothpaste capable of enhancing fluorine activity | |
| CN114796260B (en) | Oral care composition and preparation method thereof | |
| JPH09249541A (en) | Dentifrice | |
| CN113197786A (en) | Oral bacteriostatic composition, mouth wash composition, preparation method and application thereof | |
| WO1992018091A1 (en) | Antimicrobial oral compositions | |
| WO2014036564A1 (en) | Oral care composition for promoting and maintaining oral health and method of forming and using same | |
| JP4873154B2 (en) | Liquid oral composition | |
| WO1998005297A1 (en) | Composition for treating periodontitis | |
| CN105213216B (en) | A kind of natural disaccharide antibacterial shield tooth gargle and preparation method thereof | |
| CN102525833A (en) | Anti-caries mouthwash composition | |
| JP2022103980A (en) | Composition for oral cavity | |
| CN115177543B (en) | Antibacterial caries preventing composition containing L-lactate, oral care product and preparation method and application thereof | |
| RU2813879C1 (en) | Anti-inflammatory composition (versions) for local application in oral cavity and upper respiratory tract | |
| CN109512683A (en) | A kind of povidone iodine composition and the preparation method and application thereof | |
| JP3022047B2 (en) | Oral composition | |
| EP3914349B1 (en) | Composition for the treatment or prevention of infections and inflammations | |
| WO2023187028A1 (en) | Mouthwash composition comprising one or more strontium salt | |
| EP0250547A1 (en) | Composition for the treatment of periodontal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |